Laboratory Corporation of America Holdings (LH) Company Bio
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. The company offers a range of clinical laboratory tests and procedures, such as blood chemistry analysis, urinalysis, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, STD tests, HCV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of diseases. The company was founded in 1971 and is based in Burlington, North Carolina.
LH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Laboratory Corp Of America Holdings. To summarize, we found that Laboratory Corp Of America Holdings ranked in the 48th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Laboratory Corp Of America Holdings ended up being:
The company's balance sheet shows it gets 71% of its capital from equity, and 29% of its capital from debt. Notably, its equity weight is greater than just 24.63% of US equities in the Healthcare sector yielding a positive free cash flow.
Laboratory Corp Of America Holdings's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 17.52% of tickers in our DCF set.
Laboratory Corp Of America Holdings's effective tax rate, as measured by taxes paid relative to net income, is at 24 -- greater than 86.79% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Laboratory Corp Of America Holdings? See ACIU, HCSG, HSIC, EDAP, and GILD.
LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research.
In this article we will check out the progression of hedge fund sentiment towards Laboratory Corp. of America Holdings (NYSE:LH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their […]